|
Nanobiotix S.A. (NBTX) DCF Valuation
FR | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Nanobiotix S.A. (NBTX) Bundle
Streamline your analysis and improve precision with our [NBTX] DCF Calculator! Utilizing real data from Nanobiotix S.A. and customizable assumptions, this tool empowers you to forecast, analyze, and value [Company] like a seasoned investor.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .1 | .1 | .0 | 5.0 | 37.7 | 46.5 | 57.4 | 70.8 | 87.4 | 107.8 |
| Revenue Growth, % | 0 | -26.47 | -80 | 47660 | 658.12 | 23.38 | 23.38 | 23.38 | 23.38 | 23.38 |
| EBITDA | -46.6 | -32.8 | -47.5 | -47.0 | -24.7 | -43.3 | -53.4 | -65.9 | -81.4 | -100.4 |
| EBITDA, % | -65845.59 | -62988 | -456050 | -945.37 | -65.42 | -93.08 | -93.08 | -93.08 | -93.08 | -93.08 |
| Depreciation | 1.8 | 1.8 | 1.6 | 1.6 | .6 | 31.0 | 38.2 | 47.2 | 58.2 | 71.8 |
| Depreciation, % | 2602.94 | 3510 | 15600 | 31.41 | 1.52 | 66.59 | 66.59 | 66.59 | 66.59 | 66.59 |
| EBIT | -48.5 | -34.6 | -49.1 | -48.6 | -25.2 | -43.5 | -53.6 | -66.2 | -81.6 | -100.7 |
| EBIT, % | -68448.53 | -66498 | -471650 | -976.78 | -66.94 | -93.39 | -93.39 | -93.39 | -93.39 | -93.39 |
| Total Cash | 36.6 | 124.1 | 87.4 | 43.1 | 78.4 | 46.5 | 57.4 | 70.8 | 87.4 | 107.8 |
| Total Cash, percent | .1 | .2 | .8 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | 4.0 | 7.2 | .1 | 3.1 | 21.1 | 26.0 | 32.1 | 39.6 | 48.8 |
| Account Receivables, % | 16.18 | 7760 | 69260 | 2.11 | 8.19 | 45.3 | 45.3 | 45.3 | 45.3 | 45.3 |
| Inventories | 2.8 | -42.0 | -3.2 | 3.1 | .2 | -3.4 | -4.3 | -5.2 | -6.5 | -8.0 |
| Inventories, % | 3927.94 | -80640 | -30430 | 62.42 | 0.55236 | -7.41 | -7.41 | -7.41 | -7.41 | -7.41 |
| Accounts Payable | 6.4 | 5.8 | 5.2 | 4.2 | 7.0 | 37.4 | 46.2 | 57.0 | 70.3 | 86.7 |
| Accounts Payable, % | 9044.12 | 11148 | 49960 | 83.73 | 18.49 | 80.44 | 80.44 | 80.44 | 80.44 | 80.44 |
| Capital Expenditure | -1.5 | -.1 | -.2 | -.1 | -.4 | -28.2 | -34.8 | -42.9 | -52.9 | -65.3 |
| Capital Expenditure, % | -2123.53 | -214 | -2330 | -1.95 | -0.93073 | -60.58 | -60.58 | -60.58 | -60.58 | -60.58 |
| Tax Rate, % | -0.30318 | -0.30318 | -0.30318 | -0.30318 | -0.30318 | -0.30318 | -0.30318 | -0.30318 | -0.30318 | -0.30318 |
| EBITAT | -48.5 | -34.6 | -49.1 | -48.6 | -25.3 | -43.5 | -53.6 | -66.2 | -81.6 | -100.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -44.5 | 7.2 | -90.3 | -47.3 | -22.4 | -24.5 | -45.5 | -56.2 | -69.3 | -85.5 |
| WACC, % | 12.2 | 12.2 | 12.2 | 12.2 | 12.2 | 12.2 | 12.2 | 12.2 | 12.2 | 12.2 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -189.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -87 | |||||||||
| Terminal Value | -855 | |||||||||
| Present Terminal Value | -481 | |||||||||
| Enterprise Value | -670 | |||||||||
| Net Debt | -26 | |||||||||
| Equity Value | -645 | |||||||||
| Diluted Shares Outstanding, MM | 37 | |||||||||
| Equity Value Per Share | -17.46 |
What You Will Receive
- Pre-Filled Financial Model: Nanobiotix S.A.’s actual data enables accurate DCF valuation.
- Comprehensive Forecast Control: Modify revenue growth, margins, WACC, and other essential drivers.
- Real-Time Calculations: Automatic updates allow you to view results instantly as you make adjustments.
- Professional-Grade Template: A polished Excel file crafted for high-level valuation.
- Customizable and Reusable: Designed for versatility, facilitating repeated use for in-depth forecasts.
Key Features
- Comprehensive NBTX Data: Loaded with Nanobiotix's historical performance metrics and future growth projections.
- Customizable Assumptions: Tailor inputs for revenue growth, profit margins, discount rates, taxation, and capital investments.
- Interactive Valuation Framework: Real-time adjustments to Net Present Value (NPV) and intrinsic value based on user-defined parameters.
- Scenario Analysis: Develop various forecasting scenarios to assess different valuation possibilities.
- Intuitive Interface: Designed for ease of use, catering to both seasoned professionals and newcomers.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Nanobiotix data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Nanobiotix’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose Nanobiotix S.A. (NBTX)?
- Innovative Solutions: Cutting-edge technology aimed at revolutionizing cancer treatment.
- Proven Expertise: Backed by a team of specialists with extensive experience in nanomedicine.
- Robust Pipeline: A diverse range of product candidates in various stages of development.
- Commitment to Quality: Adherence to the highest standards in research and clinical trials.
- Global Reach: Collaborations with leading institutions and healthcare providers worldwide.
Who Should Use This Product?
- Healthcare Researchers: Explore innovative nanomedicine applications and analyze clinical data.
- Academics: Integrate cutting-edge nanotechnology models into your studies or research projects.
- Investors: Evaluate your investment strategies and assess the potential of Nanobiotix S.A. (NBTX).
- Pharmaceutical Analysts: Enhance your analysis with a customizable model focused on nanotechnology advancements.
- Biotech Entrepreneurs: Understand how leading companies like Nanobiotix S.A. (NBTX) approach market challenges.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Nanobiotix S.A. (NBTX) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Nanobiotix S.A. (NBTX).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.